Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

270 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
Germano G, Lamba S, Rospo G, Barault L, Magrì A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. Germano G, et al. Among authors: bartolini a. Nature. 2017 Dec 7;552(7683):116-120. doi: 10.1038/nature24673. Epub 2017 Nov 29. Nature. 2017. PMID: 29186113 Free article.
BRAF V600E is a determinant of sensitivity to proteasome inhibitors.
Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. Zecchin D, et al. Among authors: bartolini a. Mol Cancer Ther. 2013 Dec;12(12):2950-61. doi: 10.1158/1535-7163.MCT-13-0243. Epub 2013 Oct 9. Mol Cancer Ther. 2013. PMID: 24107445 Free article.
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A. Russo M, et al. Among authors: bartolini a. Cancer Discov. 2016 Jan;6(1):36-44. doi: 10.1158/2159-8290.CD-15-0940. Epub 2015 Nov 6. Cancer Discov. 2016. PMID: 26546295 Free article.
A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility.
Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. Vecchione L, et al. Among authors: bartolini a. Cell. 2016 Apr 7;165(2):317-30. doi: 10.1016/j.cell.2016.02.059. Cell. 2016. PMID: 27058664 Free article.
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer.
Bartolini A, Cardaci S, Lamba S, Oddo D, Marchiò C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Corà D, Di Nicolantonio F, Marchiò S. Bartolini A, et al. Clin Cancer Res. 2016 Oct 1;22(19):4923-4933. doi: 10.1158/1078-0432.CCR-15-2664. Epub 2016 May 3. Clin Cancer Res. 2016. PMID: 27143691 Free article.
Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Oddo D, et al. Among authors: bartolini a. Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16. Cancer Res. 2016. PMID: 27312529 Free PMC article.
Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.
Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Van Emburgh BO, et al. Among authors: bartolini a. Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665. Nat Commun. 2016. PMID: 27929064 Free PMC article.
Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A. Siravegna G, et al. Among authors: bartolini a. Ann Oncol. 2017 Jun 1;28(6):1302-1308. doi: 10.1093/annonc/mdx095. Ann Oncol. 2017. PMID: 28368455 Free article.
Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.
Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fucà G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. Oddo D, et al. Among authors: bartolini a. Br J Cancer. 2017 Jul 25;117(3):347-352. doi: 10.1038/bjc.2017.196. Epub 2017 Jun 27. Br J Cancer. 2017. PMID: 28654634 Free PMC article.
270 results